Compare Agilent Technologies Inc (A) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Roundhill Magnificent Seven ETF — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Roundhill Magnificent Seven ETF trades at $68.43. The key difference: Agilent Technologies Inc pays a 0.69% dividend while Roundhill Magnificent Seven ETF pays none. Which is the better fit depends on your goals.
| A | MAGS | |
|---|---|---|
Market Cap | $42.00B | — |
Sector | Health | Sector/Thematic |
52-Week High | $157.20 | $70.94 |
52-Week Low | $110.24 | $55.39 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
MAGS trades at $69.07, up 0.71% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights underperformance versus the S&P 500 and concerns over AI spending pressure on big tech balance sheets. The ETF has gained 181% since launch but faces challenges from equal-weighted concentration in the Magnificent Seven stocks.
The outlook is mixed: technical strength supports near-term upside, but fundamental risks from high AI capital expenditure and shifting investor sentiment toward broader market exposure pose headwinds. Investment opportunity hinges on AI revenue growth outpacing costs, while key risks include sector rotation and valuation compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
